Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages

1  Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown 26505; 2  Department of Physiology, West Virginia University School of Medicine, Morgantown, West Virginia 26506; and 3  Department of Pediatrics, Medical University of South Carolina, Charleston...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of physiology. Lung cellular and molecular physiology 1999-01, Vol.276 (1), p.186-L196
Hauptverfasser: Miles, P. R, Bowman, L, Rao, K. M. K, Baatz, J. E, Huffman, L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1  Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown 26505; 2  Department of Physiology, West Virginia University School of Medicine, Morgantown, West Virginia 26506; and 3  Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425-3313 The objectives of this investigation were 1 ) to report that pulmonary surfactant inhibits lipopolysaccharide (LPS)-induced nitric oxide (· NO) production by rat alveolar macrophages, 2 ) to study possible mechanisms for this effect, and 3 ) to determine which surfactant component(s) is responsible. · NO produced by the cells in response to LPS is due to an inducible · NO synthase (iNOS). Surfactant inhibits LPS-induced · NO formation in a concentration-dependent manner; · NO production is inhibited by ~50 and ~75% at surfactant levels of 100 and 200 µg phospholipid/ml, respectively. The inhibition is not due to surfactant interference with the interaction of LPS with the cells or to disruption of the formation of iNOS mRNA. Also, surfactant does not seem to reduce · NO formation by directly affecting iNOS activity or by acting as an antioxidant or radical scavenger. However, in the presence of surfactant, there is an ~80% reduction in the amount of LPS-induced iNOS protein in the cells. LPS-induced · NO production is inhibited by Survanta, a surfactant preparation used in replacement therapy, as well as by natural surfactant. · NO formation is not affected by the major lipid components of surfactant or by two surfactant-associated proteins, surfactant protein (SP) A or SP-C. However, the hydrophobic SP-B inhibits · NO formation in a concentration-dependent manner; · NO production is inhibited by ~50 and ~90% at SP-B levels of 1-2 and 10 µg/ml, respectively. These results show that lung surfactant inhibits LPS-induced · NO production by alveolar macrophages, that the effect is due to a reduction in iNOS protein levels, and that the surfactant component responsible for the reduction is SP-B. lipopolysaccharide; surfactant protein B; hydrophobic surfactant proteins; inducible nitric oxide synthase
ISSN:1040-0605
0002-9513
1522-1504
DOI:10.1152/ajplung.1999.276.1.l186